13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001665077
Total reported value
$383.2M
$383.2M
12 檔
38.0%
During the Q4 2025 filing period, Sand Grove Capital Management LLP (CIK: 0001665077) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $383.2M across 12 reported positions.
Sand Grove Capital Management LLP executed strategic sector rebalancing during Q4 2025, establishing 9 new positions while fully exiting 9 holdings and trimming 0 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TXNM | Txnm Energy Inc | Stock-Utilities | 11.91% | -1.21% | +0.59% | |
| 2 | WBD | Warner Bros Discovery Inc | Stock-Comm Services | 9.94% | +1.33% | — | |
| 3 | EA | Electronic Arts Inc | Stock-Comm Services | 9.67% | -1.77% | +25.45% | |
| 4 | HO1 | Hologic Inc | Stock-Other | 9.54% | — | — | |
| 5 | NSC | Norfolk Southern CORP | Stock-Industrials | 8.30% | +1.37% | +0.47% | |
| 6 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 8.11% | — | — | |
| 7 | DVAX | Dynavax Technologies CORP | Stock-Other | 7.97% | — | — | |
| 8 | AM6 | Amicus Therapeutics Inc | Stock-Other | 7.95% | — | — | |
| 9 | EXK | Exact Sciences CORP | Stock-Materials | 7.88% | — | — | |
| 10 | KVUE | Kenvue Inc | Stock-Consumer Staples | 7.43% | — | — | |
| 11 | CDTX | Cidara Therapeutics Inc | Stock-Other | 6.05% | — | — | |
| 12 | AXTA | Axalta Coating Systems Ltd. | Stock-Materials | 5.25% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EA | Electronic Arts Inc | -1.3% | +25.45% | Add |
| 2 | NSC | Norfolk Southern CORP | -4.1% | +0.47% | Add |
| 3 | TXNM | Txnm Energy Inc | -4.5% | +0.59% | Add |
| 4 | WBD | Warner Bros Discovery Inc | — | NEW | New buy |
| 5 | HO1 | Hologic Inc | — | NEW | New buy |
| 6 | KEL | Kellanova | — | EXIT | Sold out |
| 7 | RNAGBP | Avidity Biosciences Inc | — | NEW | New buy |
| 8 | DVAX | Dynavax Technologies CORP | — | NEW | New buy |
| 9 | AM6 | Amicus Therapeutics Inc | — | NEW | New buy |
| 10 | EXK | Exact Sciences CORP | — | NEW | New buy |
| 11 | ✓ | Merus N V | — | EXIT | Sold out |
| 12 | STAA | Staar Surgical Co | — | EXIT | Sold out |
| 13 | KVUE | Kenvue Inc | — | NEW | New buy |
| 14 | ✓ | Cyberark Software LTD. Cmn | — | EXIT | Sold out |
| 15 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 16 | AXTA | Axalta Coating Systems Ltd. | — | NEW | New buy |
| 17 | OMC | Omnicom Group | — | EXIT | Sold out |
| 18 | AEBA | Allete Inc | — | EXIT | Sold out |
| 19 | SU6 | Surmodics Inc | — | EXIT | Sold out |
| 20 | CCRN | Cross Country Healthcare Inc | — | EXIT | Sold out |
| 21 | RKT | Rocket Cos Inc-class A | — | EXIT | Sold out |
According to official SEC Form 13F filings, Sand Grove Capital Management LLP reported a total U.S. public equity portfolio value of $383.2M across 12 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TXNM, WBD, EA) accounted for 38.0% of total reported equity market value during Q4 2025.
Top New Position Initiated
WBD
市值: $29.3M
Top Position Liquidated / Trimmed
KEL
前期市值: $26.7M
During Q4 2025, Sand Grove Capital Management LLP's top holdings by market value included TXNM (11.9%)、WBD (9.9%)、EA (9.7%). The largest single position, TXNM, represented 11.9% of total portfolio value.
In Q4 2025, Sand Grove Capital Management LLP made 21 total portfolio adjustments, initiating 9 new buys, adding to 3 positions, trimming 0 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.